Physician profile
Jason K Winterbottom
NPI 1114901568
$6,497.84
in general payments reported to CMS, 2019-2025
23 companies · $651 in 2025
The $651 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $601 · 2021: $1,023 · 2022: $1,305 · 2023: $584 · 2024: $1,057 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,470.93 | 2019-2025 | Myday Contact Lens, Cvi Contact Lens, Onefit Contact Lens |
| Alcon Vision LLC | $1,337.33 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Bausch & Lomb Americas INC. | $625.44 | 2022-2025 | Infuse, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $432.81 | 2019-2022 | |
| Abbvie INC. | $414.13 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $394.65 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $353.51 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $259.30 | 2020-2024 | |
| Allergan, INC. | $254.93 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $150.26 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $149.23 | 2024-2025 | Xdemvy |
| Alexion Pharmaceuticals, INC. | $111.29 | 2019 | |
| Astellas Pharma US INC | $106.78 | 2024 | Izervay |
| Visioneering Technologies, INC. | $95.00 | 2019-2023 | |
| Horizon Therapeutics Plc | $93.37 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $91.53 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $37.16 | 2024 | Tyrvaya, Ryzumvi |
| Synergeyes, INC. | $24.20 | 2021 | |
| Biotissue Holdings INC. | $22.93 | 2019 | |
| Tearlab Corp | $22.33 | 2022 | |
| Dompe US, INC. | $20.84 | 2021 | |
| The Walman Optical Company | $17.11 | 2025 | |
| Lkc Technologies, INC. | $12.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Winterbottom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.